Potential Microbiological Effects of Higher Dosing of Echinocandins.

Détails

Ressource 1Télécharger: REF.pdf (271.09 [Ko])
Etat: Public
Version: Final published version
Licence: Non spécifiée
It was possible to publish this article open access thanks to a Swiss National Licence with the publisher.
ID Serval
serval:BIB_3B87BFE7C335
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Potential Microbiological Effects of Higher Dosing of Echinocandins.
Périodique
Clinical Infectious Diseases
Auteur⸱e⸱s
Steinbach W.J., Lamoth F., Juvvadi P.R.
ISSN
1537-6591 (Electronic)
ISSN-L
1058-4838
Statut éditorial
Publié
Date de publication
2015
Peer-reviewed
Oui
Volume
61 Suppl 6
Pages
S669-S677
Langue
anglais
Résumé
The antifungal "paradoxical effect" has been described as the reversal of growth inhibition at high doses of echinocandins, most usually caspofungin. This microbiological effect appears to be a cellular compensatory response to cell wall damage, resulting in alteration of cell wall content and structure as well as fungal morphology and growth. In vitro studies demonstrate this reproducible effect in a certain percentage of fungal isolates, but animal model and clinical studies are less consistent. The calcineurin and Hsp90 cell signaling pathways appear to play a major role in regulating these cellular and structural changes. Regardless of the clinical relevance of this paradoxical growth effect, understanding the specific actions of echinocandins is paramount to optimizing their use at either standard or higher dosing schemes, as well as developing future improvements in our antifungal arsenal.
Mots-clé
Animals, Antifungal Agents/administration & dosage, Antifungal Agents/adverse effects, Aspergillosis/drug therapy, Aspergillosis/microbiology, Aspergillus/drug effects, Aspergillus/growth & development, Calcineurin/metabolism, Candida/drug effects, Candida/genetics, Candidiasis/drug therapy, Candidiasis/microbiology, Cell Wall/drug effects, Cell Wall/metabolism, Clinical Trials as Topic, Disease Models, Animal, Dose-Response Relationship, Drug, Drug Tolerance, Echinocandins/administration & dosage, Echinocandins/adverse effects, Fungal Proteins/metabolism, HSP90 Heat-Shock Proteins/metabolism, Humans
Pubmed
Web of science
Open Access
Oui
Création de la notice
11/01/2016 18:35
Dernière modification de la notice
21/11/2022 9:27
Données d'usage